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Burkholderia pseudomallei is the Gram-negative bacterial pathogen responsible for the disease 
melioidosis. B. pseudomallei establishes disease in susceptible individuals through multiple 
routes of infection, all of which may proceed to a septicemic disease associated with a high 
mortality rate. B. pseudomallei opportunistically infects humans and a wide range of animals 
directly from the environment, and modeling of experimental melioidosis has been conducted in 
numerous biologically relevant models including mammalian and invertebrate hosts. This review 
seeks to summarize published findings related to established animal models of melioidosis, with 
an aim to compare and contrast the virulence of B. pseudomallei in these models. The effect of 
the route of delivery on disease is also discussed for intravenous, intraperitoneal, subcutaneous, 
intranasal, aerosol, oral, and intratracheal infection methodologies, with a particular focus on 
how they relate to modeling clinical melioidosis. The importance of the translational validity 
of the animal models used in B. pseudomallei research is highlighted as these studies have 
become increasingly therapeutic in nature.
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 particularly sensitive to infection including goats, sheep, camels, 
and alpacas (Choy et al., 2000). Pigs and deer are moderately 
sensitive to infection, while cats, dogs, birds, and cattle are only 
partially sensitive to infection (Choy et al., 2000). Numerous 
additional animal species have been reported to contract melio-
idosis, many of which represent introductions of non-native 
species to B. pseudomallei-associated environments, as in the 
case of zoos and aquariums in endemic areas (Hicks et al., 2000; 
Sprague and Neubauer, 2004).
Genome sequencing has revealed that B. pseudomallei is closely 
related to Burkholderia mallei, an obligate mammalian pathogen 
responsible for the disease glanders. B. mallei is considered to be 
a clone of B. pseudomallei, having underwent genomic reduction 
which decreased its genome size from 7.2 to 5.8 Mb (Nierman et al., 
2004). B. mallei does not possess ability to survive in the environ-
ment for prolonged periods of time, and the natural host range 
has been reduced to soliped reservoirs from which opportunistic 
zoonotic infections occur. Successful eradication of B. mallei from 
westernized countries over the last century was made possible by 
the limited host range of B. mallei, and a simple diagnostic test that 
identified infected horses to be culled (Derbyshire, 2002).
Both B. pseudomallei and B. mallei are Category B Select Agent 
BSL-3 pathogens identified to possess a potential for bioweaponiza-
tion. Licensed vaccines are not currently available for prophylactic 
protection against either pathogen and post-exposure prophylaxis 
options are limited. Thus, numerous studies have described animal 
models used in the study of the diseases caused by these closely 
related organisms with an aim to facilitate the investigation of 
novel therapeutics. A much larger body of research has focused 
on modeling the disease of B. pseudomallei in animals, and as 
such, this review will focus primarily on summarizing our current 
understanding of disease progression and host immune response 
in laboratory models of animal melioidosis.
IntroductIon
Burkholderia pseudomallei is the etiologic agent of the disease 
melioidosis which is endemic in Southeast Asia and northern 
Australia. B. pseudomallei can be cultured from tropical soils with-
out requiring a host for environmental persistence (Kaestli et al., 
2009), and B. pseudomallei infections of both mammalian and non-
mammalian hosts are considered to be opportunistic. Melioidosis 
is historically associated with a high mortality rate due to the speed 
with which septicemia develops and the inherent resistance of the 
bacteria to several classes of antibiotics. The overall mortality rate 
of melioidosis in endemic areas of Australia is 19%, while it is 50% 
in Thailand, likely reflecting the differing availability of efficacious 
treatment (Limmathurotsakul et al., 2010a).
Exposure to B. pseudomallei in endemic areas is considered 
high, with seroconversion rates as high as 80% by the age of 4, 
whereas only 0.0045% of the population annually contracts disease 
(Leelarasamee, 1998). The significant gap between the incidence 
of exposure and disease suggests the role of additional factors 
such as dose, route of infection, and host susceptibility to disease. 
B. pseudomallei is present in tropical soils at an average density of 
700 CFU/g of soil in rice fields where the likelihood for opportun-
istic interaction with humans is high, whereas transient increases 
in the soil titer to >10,000 CFU/g may increase the likelihood that 
susceptible individuals may contract disease (Limmathurotsakul 
et al., 2010b). Human risk factors for melioidosis include diabetes, 
severe alcoholism, thalassemia, and renal complications, where dia-
betes mellitus represents the predominant risk factor in 37–60% 
of melioidosis patients (Cheng and Currie, 2005).
A wide variety of animals are opportunistically infected with 
B. pseudomallei from the environment, where the increased 
incidence of melioidosis amongst certain animal species has 
led to conclusions regarding the susceptibility to infection. In 
northern Australia, several livestock species are considered 
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cell biology in mice, making the mouse an attractive  translational 
research model for studying disease. This section will review our 
current understanding of disease progression and host response to 
B. pseudomallei in the mouse model.
Mouse straIn susceptIbIlIty
Numerous mouse strains have been used to model melioidosis, 
including BALB/c, C57BL/6, SWISS, CBA, CD-1, DBA/2, C3H/
HeN, Namru Albino, Taylor Outbred (TO), 129/SvEv, and SCID 
mice, however little is known about the effect of the host mouse 
strain in mediating susceptibility to infection with B. pseudomal-
lei. BALB/c mice have long been known to represent a susceptible 
mouse strain which are used to model the acute form of the disease, 
whereas C57BL/6 are thought to be relatively resistant to B. pseu-
domallei infection resulting in a chronic disease model (Leakey 
et al., 1998). Thus, by several routes of infection, fewer organisms 
are required to establish disease in the BALB/c model as compared 
to the C57BL/6 mice. The specific fold difference in susceptibility 
to infection of these two mouse strains varies not only by route of 
infection, but also on strain of B. pseudomallei used in the infec-
tion challenge. By intravenous infection, 102- to 6.25 × 104-fold 
more B. pseudomallei are required to infect C57BL/6 mice, 13- to 
2 × 104-fold by intraperitoneal infection, 18- to 1 × 105-fold by 
subcutaneous infection or 13- to 390-fold by intranasal infection 
(Tables 1 and 2). A log-transformed average of this data suggests 
that a ∼200-fold difference in susceptibility exists between BALB/c 
and C57BL/6 melioidosis models.
Several studies have further investigated the susceptibility of 
other mouse strains to infection with B. pseudomallei. A study using 
age and sex matched mice challenged with a common strain of B. 
pseudomallei revealed that the susceptibility of four mouse strains 
to intravenous infection was ordered as BALB/c > DBA/2 > C3H/
HeN >> C57BL/6 (Hoppe et al., 1999). Another study has reported 
that CBA mice are approximately 40-fold more sensitive to infection 
than BALB/c mice (Manzeniuk et al., 1999), and may represent the 
most sensitive mouse model for the study of melioidosis. The 129/
SvEv mice are 23-fold more sensitive than BALB/c mice and TO 
mice are over 200-fold more resistant than BALB/c mice (Table 1), 
indicating that C57BL/6 mice may be as resistant to infection as out-
bred mice. CD-1 mice are the only additional outbred mouse strain 
used in the study of B. pseudomallei pathogenesis (Fisher et al., 
1971), however LD
50
 information is not available to address sus-
ceptibility to melioidosis. Summarizing the findings of these stud-
ies, the ranked susceptibility of mice to B. pseudomallei infection 
may be represented as CBA > 129/SvEv > BALB/c > DBA/2 > C3H/
HeN >> (C57BL/6 and TO).
routes of InfectIon
Naturally occurring infections in the human population occur via 
several possible routes of infection including inhalation and inges-
tion, while percutaneous inoculations are thought to represent the 
primary route of infection in endemic areas (Currie et al., 2000c). 
These naturally occurring routes of infection have been studied in 
several different animal species with the aim of modeling clinical 
melioidosis. While percutaneous inoculation is thought to rep-
resent the primary natural route of infection, there has been a 
recent shift toward animal respiratory disease models. Biodefense 
clInIcal MelIoIdosIs
Burkholderia pseudomallei is maintained in tropical soils worldwide 
and opportunistically infects a wide range of hosts including mam-
malian, avian, and invertebrate species. B. pseudomallei is infectious 
to humans by several routes of infection including percutaneous 
inoculation, ingestion, inhalation, and less commonly by sexual 
transmission or mother-to-fetus transmission (McCormick et al., 
1975; Currie et al., 2000c; Inglis et al., 2000a; Abbink et al., 2001). 
In endemic areas, percutaneous inoculation is thought to represent 
the most common mechanism of transmission, although identi-
fying the route of infection in the absence of a clear inoculating 
event may be difficult due to the systemic spread of melioidosis to 
all major organs, rather than containment of disease to the site of 
infection (Currie et al., 2000c).
Melioidosis is a disease that manifests with a wide range of 
symptoms including pneumonia, skin lesions, neurological infec-
tions, osteomyelitis, genitourinary infections, prostatic abscesses, 
pericarditis, and septic arthritis (Currie et al., 2000b; Morse et al., 
2009; Chetchotisakd et al., 2010). Pulmonary infections occur in 
approximately half of all melioidosis patients, and represents the 
most common presentation of disease. The incubation period 
averages 9 days before the onset of symptoms (Currie et al., 
2000c), and septicemia is a highly fatal progression of melio-
idosis with mortality approaching 70% for untreated disease 
(Chaowagul et al., 1989).
Diagnostic imaging of melioidosis has revealed that the lung is 
the most frequently affected organ in clinical patients (Muttarak 
et al., 2008; Lim and Chong, 2010). Liver and spleen pathology is 
observed in approximately half of melioidosis patients, suggesting 
that colonization of these organs typically occurs at reduced rates 
relative to the lung (Lim and Chong, 2010). The size and frequency 
of splenic lesions in melioidosis are unique as many bacterial patho-
gens do not share the same level of spleen pathology as that elicited 
by B. pseudomallei (Laopaiboon et al., 2009). Histological analyses 
have found that B. pseudomallei may be found within macrophages 
in the lung, liver, and spleen as well as in extracellular niches (Wong 
et al., 1995, 1996).
Cytokine profiles of clinical melioidosis indicate that B. pseu-
domallei elicits a strong proinflammatory response. The synergis-
tic production of IFN-γ by IL-12, IL-15, and IL-18 was observed 
in melioidosis patients with all four cytokines present in plasma 
at levels above background in non-septicemic patients, and the 
onset of septicemic melioidosis further elevated the levels of these 
proinflammatory cytokines (Lauw et al., 1999). Similarly, fatal sep-
ticemic melioidosis is associated with plasma levels of the cytokines 
TNF-α, IL-6, and IL-10 that are elevated above the levels of surviv-
ing patients (Simpson et al., 2000), and the T-cell chemoattractants 
IP-10 and MIG are also elevated in melioidosis patients, particularly 
during septicemia (Lauw et al., 2000). It is not clear whether ele-
vated proinflammatory cytokine levels contribute to poor outcome 
or are solely an indicator of disease severity (Brown et al., 1991; 
Friedland et al., 1992; Suputtamongkol et al., 1992).
Mouse Model
The mouse represents the most common animal model used as a sur-
rogate for the study of melioidosis. Numerous commercially avail-
able tools are available to study gene regulation,  immunology, and 
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The host environment encountered during i.p. infection involves 
host defense through peritoneal macrophages, and host susceptibil-
ity through access to major organs including the liver and spleen. 
Symptomatic disease may not occur until 6 days post-infection (Tan 
et al., 2008). The i.p. mouse model does not specifically model a natu-
ral route of infection for human melioidosis, but like the i.v. model, 
may model a traumatic percutaneous inoculation. As such, similar 
benefits and limitations exist for the i.p. model as the i.v. model where 
i.p. infections are useful for the study of rapid acute disease.
Subcutaneous
Subcutaneous (s.c.) mouse models are the third most acute models 
for study of melioidosis with LD
50
 values typically 101- to 102-fold 
higher than those of i.p. models (Table 2). This model represents a 
good physical reproduction of the percutaneous infections associ-
ated with human disease. Lesion formation at the site of percutane-
ous inoculation is not consistently observed clinically (Currie et al., 
2000c), and lesion formation has not been reported for s.c. mouse 
models. Needle inoculation by the s.c. route into the dermis and/or 
hypodermis skin layers of a mouse results in a delayed disease proc-
ess compared to other routes of infection, as s.c. infections become 
symptomatic more than 2 weeks after i.p. infected mice (Tan et al., 
2008). The host immune response to s.c. inoculation may involve 
macrophages, dendritic cells, mast cells, and lymphocytes associ-
ated with the dermis, whereas deeper inoculation of the hypodermis 
may not result in a significant initial host immune response to the 
invading bacteria. B. pseudomallei may spread through a host by 
invading blood vessels present in the hypodermal layer, and this 
physical barrier to immediate systemic spread could account for 
the delay in disease progression and ∼102-fold increase in organ-
isms required to cause disease relative to the i.v. route of infection 
(Table 2). It is notable that B. pseudomallei strain NCTC 13179 is 
reported to cause disease by s.c. inoculation of BALB/c mice with 
fewer organisms than is required by either i.p. or i.v. inoculation 
(Barnes and Ketheesan, 2005). Additional studies may be required 
to identify whether this is a unique susceptibility of BALB/c mice 
to this particular strain of B. pseudomallei.
Intranasal
The target organ of i.n. inoculation is the lung which possesses sev-
eral forms of innate immunoprotection against invading organisms. 
These host defenses include: (i) the physical barrier of mucus, (ii) 
spending following the anthrax letter attacks of September 2001 was 
pivotal in shifting this focus toward biodefense-related respiratory 
models for melioidosis.
Intravenous
Burkholderia pseudomallei infections by the intravenous (i.v.) 
route lead to a rapid disseminated infection affecting multiple 
organs, and represents the most acute disease model of melio-
idosis based on the low numbers of organisms required to cause 
disease. Infection by i.v. inoculation results in a rapidly fatal dis-
ease with mortality at 2–4 days (Leakey et al., 1998) and the pri-
mary organs colonized are liver and spleen with reduced numbers 
of organisms colonizing the lung (Hoppe et al., 1999). Systemic 
spread to the lung following non-pulmonary infection is consist-
ent with clinical data where reports of percutaneous inoculation 
are frequently associated with presentation of pulmonary disease 
(Currie et al., 2000c).
Due to the very acute nature of the i.v. infection model, low 
virulence strains of B. pseudomallei or resistant strains of mice 
may be successfully studied in this model when disease cannot 
be achieved in more resistant models. For example, the i.v. model 
has been used to characterize a 6 log range of disease-causing 
potential of over 40 B. pseudomallei strains of clinical, veterinary, 
and environmental origin (Ulett et al., 2001). The i.v. model 
is also ideally situated to investigate therapeutic intervention 
for the most acute form of melioidosis. While the i.v. model 
enhances the acute disease potential for difficult to study strains 
of B.  pseudomallei and animals, the limitations of the i.v. model 
relate to the short time span of melioidosis for basic studies 
of disease progression using highly virulent bacterial strains or 
susceptible animal models.
Intraperitoneal
The infection of mice by the intraperitoneal (i.p.) route is the sec-
ond most acute mouse model of melioidosis as assessed by LD
50
 
values. The i.p. LD
50
 values either closely mimic those identified 
for i.v. infection, or may be up to 102-fold higher, depending on 
the bacteria and mouse strains used in the challenge (Table 2). 
B. pseudomallei i.p. infection results in colonization of the liver 
and spleen, whereas the lung is either not significantly affected 
(Santanirand et al., 1999) or colonized at a reduced level relative 
to respiratory disease models (Atkins et al., 2002).
Table 1 | Effect of mouse species on disease outcome.
Route of Mouse Sex Age Bacterial LD50 or ID50 Duration of Reference 
infection strain   strain (CFU) observation
i.p. BALB/c N.I. N.I. A2 19 N.I. Taweechaisupapong et al. (2005)
i.p. BALB/c Female 6–8 weeks A2 20 30 days Srilunchang et al. (2009)
i.p. C57BL/6 Female 6–8 weeks A2 3 × 102 30 days Srilunchang et al. (2009)
i.v. BALB/c Mix 6–10 weeks TGH 4 10 days Leakey et al. (1998)
i.v. C57BL/6 Mix 6–10 weeks TGH 2.5 × 104 10 days Leakey et al. (1998)
i.p. TO Female 10–12 weeks 708a >5 × 105 65 days Santanirand et al. (1999)
i.p. 129/SvEv N.I. N.I. 708a 1 × 102 65 days Santanirand et al. (1999)
i.p. BALB/c N.I. N.I. 708a 2.31 × 103 N.I. Titball et al. (2008)
i.p., Intraperitoneal; i.v., intravenous; N.I., not indicated.
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Table 2 | Effect of route of infection on disease outcome.
Route of Mouse Sex Age Bacterial LD50 or ID50 Duration of Reference 
infection strain   strain (CFU) observation
i.v. BALB/c Female 8–10 weeks NCTC 7431 1 × 103 42 days Hoppe et al. (1999)
i.v. DBA/2 Female 8–10 weeks NCTC 7431 3 × 103 42 days Hoppe et al. (1999)
i.v. C3H/HeN Female 8–10 weeks NCTC 7431 6 × 103 42 days Hoppe et al. (1999)
i.v. C57BL/6 Female 8–10 weeks NCTC 7431 1 × 105 42 days Hoppe et al. (1999)
i.v. BALB/c Female 8–10 weeks E8 <10 42 days Hoppe et al. (1999)
i.p. BALB/c N.D. 6 weeks E8 14 28 days Smith et al. (1997)
i.n. BALB/c Female 8–12 weeks E8 <10 N.I. Pilatz et al. (2006)
i.v. C57BL/6 Mix 8–10 weeks NCTC 13178 5 × 103 10 days Barnes and Ketheesan (2005)
i.v. BALB/c Mix 8–16 weeks NCTC 13178(CL24) 10 10 days Ulett et al. (2001)
i.v. BALB/c Mix 8–10 weeks NCTC 13178 <10 10 days Barnes and Ketheesan (2005)
i.p. C57BL/6 Mix 8–10 weeks NCTC 13178 9.7 × 103 10 days Barnes and Ketheesan (2005)
i.p. BALB/c Mix 8–10 weeks NCTC 13178 12 10 days Barnes and Ketheesan (2005)
s.c. C57BL/6 Mix 8–10 weeks NCTC 13178 9 × 105 10 days Barnes and Ketheesan (2005)
s.c. BALB/c Mix 8–10 weeks NCTC 13178 1 × 103 10 days Barnes and Ketheesan (2005)
i.n. C57BL/6 Mix 8–10 weeks NCTC 13178 1.8 × 103 10 days Barnes and Ketheesan (2005)
i.n. BALB/c Mix 8–10 weeks NCTC 13178 1.4 × 102 10 days Barnes and Ketheesan (2005)
Transoral C57BL/6 Mix 8–10 weeks NCTC 13178 1.8 × 106 10 days Barnes and Ketheesan (2005)
Transoral BALB/c Mix 8–10 weeks NCTC 13178 7.2 × 103 10 days Barnes and Ketheesan (2005)
i.v. C57BL/6 Mix 8–10 weeks NCTC 13179 6 × 106 10 days Barnes and Ketheesan (2005)
i.v. BALB/c Mix 8–16 weeks NCTC 13179(CL07) 1.52 × 104 10 days Ulett et al. (2001)
i.v. BALB/c Mix 8–10 weeks NCTC 13179 9 × 103 10 days Barnes and Ketheesan (2005)
i.p. C57BL/6 Mix 8–10 weeks NCTC 13179 6 × 106 10 days Barnes and Ketheesan (2005)
i.p. BALB/c Mix 8–10 weeks NCTC 13179 4.7 × 105 10 days Barnes and Ketheesan (2005)
s.c. C57BL/6 Mix 8–10 weeks NCTC 13179 >108 10 days Barnes and Ketheesan (2005)
s.c. BALB/c Mix 8–10 weeks NCTC 13179 9 × 102 10 days Barnes and Ketheesan (2005)
i.n. C57BL/6 Mix 8–10 weeks NCTC 13179 >108 10 days Barnes and Ketheesan (2005)
i.n. BALB/c Mix 8–10 weeks NCTC 13179 1.9 × 106 10 days Barnes and Ketheesan (2005)
Transoral C57BL/6 Mix 8–10 weeks NCTC 13179 >108 10 days Barnes and Ketheesan (2005)
Transoral BALB/c Mix 8–10 weeks NCTC 13179 4.8 × 106 10 days Barnes and Ketheesan (2005)
i.p. BALB/c N.I. N.I. KWH 5.65 × 103 30 days Chua et al. (2003)
i.p. BALB/c Female 4–8 weeks KWH 1.1 × 103 10 days Tan et al. (2008)
i.p. C57BL/6 Female 4–8 weeks KWH >5.88 × 104 10 days Tan et al. (2008)
s.c. BALB/c Female 4–8 weeks KWH 5 × 105 20 days Tan et al. (2008)
s.c. C57BL/6 Female 4–8 weeks KWH 2.3 × 107 20 days Tan et al. (2008)
i.n. BALB/c N.D. 5–6 weeks KWH 45 10 days Liu et al. (2002)
i.n. C57BL/6 N.D. 5–6 weeks KWH 4.85 × 103 10 days Liu et al. (2002)
i.n. BALB/c Female 4–8 weeks KWH 16 10 days Tan et al. (2008)
i.n. C57BL/6 Female 4–8 weeks KWH 6.23 × 103 10 days Tan et al. (2008)
Aerosol BALB/c Female 4–8 weeks KWH <20 10 days Tan et al. (2008)
Aerosol C57BL/6 Female 4–8 weeks KWH 423 10 days Tan et al. (2008)
i.p. BALB/c Female 4–8 weeks K96243 5.4 × 104 10 days Tan et al. (2008)
i.p. BALB/c Female 5–6 weeks K96243 ∼1 × 103 N.I. Harland et al. (2007)
i.p. BALB/c N.I. N.I. K96243 2.62 × 102 N.I. Titball et al. (2008)
i.p. BALB/c Female 6 weeks K96243 3.5 × 103 N.I. Sarkar-Tyson et al. (2009)
i.p. C57BL/6 Female 4–8 weeks K96243 5.3 × 106 10 days Tan et al. (2008)
s.c. BALB/c Female 4–8 weeks K96243 3 × 107 20 days Tan et al. (2008)
s.c. C57BL/6 Female 4–8 weeks K96243 5.4 × 108 20 days Tan et al. (2008)
i.n. BALB/c Female 4–8 weeks K96243 2.3 × 102 10 days Tan et al. (2008)
i.n. C57BL/6 Female 4–8 weeks K96243 1.52 × 104 10 days Tan et al. (2008)
Aerosol BALB/c Female 6 weeks K96243 5 N.I. Sarkar-Tyson et al. (2009)
i.p. BALB/c N.I. 6–8 weeks 1026b 104 30 days Wikraiphat et al. (2009)
(Continued)
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i.n. BALB/c Female 6–8 weeks 1026b 9.9 × 102 N.I. Goodyear et al. (2009)
Aerosol BALB/c Female 6–8 weeks 1026b 10 N.I. Jeddeloh et al. (2003)
Aerosol C57BL/6 Female 6–8 weeks 1026b 27 N.I. Jeddeloh et al. (2003)
i.n. BALB/c Female 6–8 weeks DD503 1.38 × 103 14 days Warawa et al. (2009)
Aerosol BALB/c Female 6–8 weeks DD503 1.47 × 103 N.I. Jeddeloh et al. (2003)
Aerosol BALB/c Female N.I. DD503 1 × 103 39 days Ulrich et al. (2004)
i.p. BALB/c N.I. N.I. BRI 53 N.I. Titball et al. (2008)
Aerosol BALB/c Female 6–8 weeks BRI 5 5 days Lever et al. (2009)
i.p. BALB/c Female 6–8 weeks NCTC 4845T 40 35 days Nelson et al. (2004)
Aerosol BALB/c Female 6–8 weeks NCTC 4845T 5 35 days Nelson et al. (2004)
i.p. BALB/c Female 4–8 weeks EB6103 3.39 × 104 10 days Tan et al. (2008)
i.p. C57BL/6 Female 4–8 weeks EB6103 >8.5 × 105 10 days Tan et al. (2008)
s.c. BALB/c Female 4–8 weeks EB6103 1.3 × 106 20 days Tan et al. (2008)
s.c. C57BL/6 Female 4–8 weeks EB6103 4.7 × 107 20 days Tan et al. (2008)
i.n. BALB/c Female 4–8 weeks EB6103 >8.5 × 102 10 days Tan et al. (2008)
i.n. C57BL/6 Female 4–8 weeks EB6103 2.2 × 104 10 days Tan et al. (2008)
i.p. Namru albino Female 2–6 months 103-67 35 N.I. Dannenberg and Scott (1958)
Aerosol Namru albino N.I. 2–6 months 103-67 16 N.I. Dannenberg and Scott (1958)
i.c. Namru albino Female 3–4 weeks 103R 1.6 × 104 N.I. Nigg et al. (1956)
i.c. Namru albino Female 3–4 weeks 103R-2 1.6 × 102 N.I. Nigg et al. (1956)
i.p. CBA N.D. N.I. C-141 5.8 × 102 45 days Manzeniuk et al. (1999)
i.p. BALB/c N.D. N.I. C-141 1.5 × 104 45 days Manzeniuk et al. (1999)
s.c. CBA N.D. N.I. C-141 2.0 × 103 45 days Manzeniuk et al. (1999)
s.c. BALB/c N.D. N.I. C-141 1.1 × 105 45 days Manzeniuk et al. (1999)
i.p. SWISS Female 8 weeks 008 4.0 × 105 42 days Valade et al. (2004)
s.c. SWISS Female 8 weeks 008 6.3 × 106 42 days Valade et al. (2004)
i.n. SWISS Female 8 weeks 008 1.6 × 102 42 days Valade et al. (2004)
i.v., Intravenous; i.p., intraperitoneal; i.n., intranasal; s.c., subcutaneous; i.c., intracranial; N.I., not indicated.
Table 2 | Continued
Route of Mouse Sex Age Bacterial LD50 or ID50 Duration of Reference 
infection strain   strain (CFU) observation
ciliary clearance of mucus from the lung, and (iii) rapid  epithelial 
cell signaling of immunoprotection, including antimicrobial pep-
tides and activation of resident alveolar macrophages. Host defense 
mechanisms of the lung trigger proinflammatory responses that are 
likely subverted by B. pseudomallei to breach the alveolar epithelial 
lining. B. pseudomallei readily colonizes the lung and is found to 
disseminate to other organs, notably the liver and spleen, following 
i.n. infection (Liu et al., 2002; Chua et al., 2003; Pilatz et al., 2006; 
Goodyear et al., 2009; Warawa et al., 2009). As discussed earlier, the 
tropism for lung colonization may be strain dependent as certain 
B. pseudomallei strains do not preferentially colonize the lung fol-
lowing intranasal delivery (Barnes and Ketheesan, 2005).
Respiratory tract infections established by intranasal (i.n.) deliv-
ery fail to follow a specific trend when comparing i.n. LD
50
 values to 
the previously described needle-associated routes of infection (i.v., 
i.p. and s.c.). Approximately 101–102 fewer organisms are required 
to cause disease by the i.n. route relative to the i.p. route (Table 2), 
with examples of 103-fold fewer organisms in the case of strain 008 
infection of SWISS mice (Valade et al., 2004). The opposite trend is 
also observed where >101-fold more of strain NCTC 13179 organ-
isms are required to cause disease by the i.n. route versus the i.p. 
route in infections of both BALB/c and C57BL/6 mice (Barnes and 
Ketheesan, 2005). Similar lack of correlation of i.v. and i.n. LD
50
 
values are also observed (Table 2). Thus, the lack of correlation of 
respiratory LD
50
 values to those of the systemic (i.v., i.p., and s.c.) 
routes suggest that some B. pseudomallei strains are more adept 
establishing respiratory infections than others, or conversely that 
strains may be more adept at establishing systemic infections. For 
example, the highly virulent B. pseudomallei strain NCTC 13178 
colonizes the lung at low levels regardless of whether it is delivered 
intranasally or by needle inoculation (Barnes and Ketheesan, 2005), 
suggesting that the high virulence of this strain may be attributed to 
its ability to rapidly disseminate and establish systemic disease rather 
than colonize the lung. Future studies will be required to identify 
genetic loci that contribute to the varied fitness of B.  pseudomallei 
to establish respiratory and/or systemic diseases.
While, i.n. infections are thought to predominantly model 
lower respiratory tract infections of the lung, several additional 
host sites are infected. Bacterial suspensions deposited at the 
anterior nares resolve into three fluid fractions localizing to: (i) 
the upper respiratory tract, (ii) the lower respiratory tract, and 
(iii) the digestive system. The swallowing of a portion of the 
inoculum leads to an infection of the digestive system, which 
is not thought to be a major route of infection. B. pseudomallei 
has been demonstrated to successfully colonize both the upper 
and lower respiratory tracts, both of which can independently 
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of the digestive system. Thus, meningitis resulting from aerosol 
 delivery is likely due to upper respiratory tract colonization lead-
ing to invasion the olfactory bulbs. As reported for the i.n. model, 
aerosol infections result in confounding meningitis and potential 
NALT-related dissemination to other organs.
The mouse upper respiratory tract anatomy differs from that of a 
human with respect to the relative size and the more significant use 
of the upper respiratory tract for olfactory purposes. Normalization 
of the average nasal cavity surface area of the mouse and human 
(Reznik, 1990) against the total lung capacity of each (Hoyt et al., 
2007) reveals that the mouse has a relative nasal cavity surface area 
of greater than 100-fold that of a human. Given the propensity for 
B. pseudomallei to colonize the mouse upper respiratory tract, and 
the over-represented surface area of the mouse nasal cavity, both 
i.n. and aerosol routes of infection will likely lead to mixed dis-
semination pathways involving the expected lower respiratory tract 
dissemination as well as over-represented upper respiratory tract 
dissemination. Furthermore, infections secondary to pneumonia 
may also present as a result of upper respiratory tract coloniza-
tion, including meningitis, otitis media, and rhinitis. These caveats 
must be addressed when interpreting findings from aerosol and 
i.n. infection models that focus on the systemic disease resulting 
from respiratory tract dissemination.
Intratracheal and oral models
Intratracheal (i.t.) instillations have not been used to model respi-
ratory melioidosis in the mouse, though they have been described 
in the rat model as discussed below. A potential benefit of the i.t. 
model is the direct delivery of organisms to the lung for the pur-
poses of modeling pulmonary disease with minimal involvement 
of the upper respiratory tract. A surgical method of i.t. infection 
of mice involves an incision to the ventral neck skin to expose the 
trachea, injection of a bacterial suspension by needle through the 
tracheal wall, followed by application of a surgical staple. This 
method has been successfully used to enhance delivery of organ-
isms specifically to the lung for several bacterial respiratory path-
ogens, including Legionella pneumophila (Brieland et al., 1994), 
Haemophilus influenza (Heitmann et al., 1999), Pseudomonas 
aeruginosa (Moser et al., 1997), Klebsiella pneumoniae (Fan et al., 
2002), and Burkholderia cepacia (Chiu et al., 2001). More recently, 
non-surgical variations of i.t. infections have been reported as 
an additional enhancement to surgical i.t. infections which avoid 
the trauma associated with surgery (Su et al., 2004; Lacher et al., 
2010). The future use of non-surgical i.t. instillation may provide 
the ability to study pulmonary melioidosis and lung-specific dis-
semination in the absence of the confounding involvement of the 
upper respiratory tract.
The investigation of oral infection was reported as part of a study 
by Barnes et al. which compared five different routes of infection 
for both BALB/c and C57BL/6 mice, using two strains of B. pseu-
domallei. The method of oral instillation reported in the study 
involved deposition of an infectious dose to the back of the throat 
(Barnes and Ketheesan, 2005). This method of infection has been 
reported by others as a transoral infection methodology affecting 
both the lung and stomach as a result of both ingestion and inha-
lation of the inoculum (Lacher et al., 2010). The transoral LD
50
 
values were higher than those identified for i.n. infection (Barnes 
lead to disseminated disease. Luminescent B. pseudomallei used 
to infect mice intranasally were found to significantly colonize 
the upper respiratory tract, as indicated by in vivo visualization, 
and were also able to disseminate to the liver and spleen (Owen 
et al., 2009). Owen et al. argued that non-pulmonary invasion 
of the nasal-associated lymphoid tissue (NALT) is a significant 
route of host entry in intranasally infected mice, leading to dis-
seminated infection of liver and spleen. Furthermore, significant 
B. pseudomallei colonization of the upper respiratory tract leads 
to meningitis through infection of the olfactory bulb, as has been 
similarly reported by others (Warawa and Gherardini, 2010). The 
upper respiratory tract represents a major site of colonization in 
intranasally infected mice as upper respiratory lavage of infected 
BALB/c and C57BL/6 mice have increased levels of the inflam-
matory cytokines IFN-γ, TNF-α and IL-1β (Liu et al., 2002). The 
clinical incidence of B. pseudomallei meningitis is considered to 
be uncommon (Currie et al., 2000a; Chadwick et al., 2002), thus 
animal models that frequently introduce meningitis may not 
accurately model clinical melioidosis. Thus, i.n. infections of mice 
may over-represent the clinical incidence of meningitis, and may 
also result in non-pulmonary dissemination via the NALT. The 
use of the i.n. model to study respiratory melioidosis benefits 
from the ease of use of the method and the relative safety to 
the researcher.
Aerosol
Aerosol infection of mice is optimized to deliver small infectious 
particles of an ideal size that are inhaled deep into the lung to 
establish pulmonary infection. The most efficacious particle size 
required to maximize pulmonary distribution will depend upon 
the dynamics of breathing, which will vary amongst species, age, 
and sex (Kim and Hu, 1998; Thomas et al., 2009). It would there-
fore be anticipated that aerosolized delivery of B. pseudomallei 
would lower the dose required to establish disease in a host, relative 
to the i.n. route. The LD
50
 values presented in Table 2 reveal that 
aerosol delivery of B. pseudomallei enhances the disease poten-
tial of strain 1026b 99-fold in BALB/c mice, whereas no change 
in the disease potential of strain DD503 is observed in BALB/c 
mice relative to i.n. delivery. Similarly, KWH infection of C57BL/6 
mice is enhanced 15-fold and K96243 infection of BALB/c mice 
is enhanced 46-fold when organisms are aerosolized rather than 
delivered i.n.. The variation in the overall effectiveness of aerosol 
delivery over i.n. delivery could be attributed to the variation of 
apparatus design and operation in different laboratories (particle 
size, whole body versus nose only, or flow rate). Therefore, aerosol 
delivery of B. pseudomallei may reduce the number of organisms 
required to establish disease, but this methodology must be opti-
mized in each laboratory.
Respiratory infections mediated by aerosolization of 
B.  pseudomallei result primarily in colonization of the lung, with 
reduced colonization of the liver and spleen as observed for the i.n. 
model (Jeddeloh et al., 2003; Lever et al., 2009). Additional host 
sites are colonized including blood and the kidneys, but impor-
tantly the brain was also shown to be colonized with significant 
numbers of B. pseudomallei (Lever et al., 2009). Like the i.n. route of 
infection, aerosol delivery of B. pseudomallei results in both upper 
and lower respiratory tract infections but without the involvement 
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Th1/Th2  balance. An investigation of the IgG subtypes produced 
during  disease indicated that C57BL/6 mice have a much higher 
relative IgG2a response than BALB/c mice, suggestive of a stronger 
Th1 response in the resistant C57BL/6 mice (Hoppe et al., 1999). 
Subsequent studies revealed that BALB/c mice were not deficient 
in production of proinflammatory Th1-type cytokines, and in fact 
produced much higher levels of such cytokines (TNF-α, IL-6, and 
IL-1β) than C57BL/6 mice (Ulett et al., 2000), arguing against proin-
flammatory deficiencies in the BALB/c melioidosis model. The pref-
erentially elevated proinflammatory cytokine response in BALB/c 
mice has also been confirmed using different bacterial strains (Ulett 
et al., 2002) and routes of infection (Liu et al., 2002).
The strength of the proinflammatory response in BALB/c mice 
was implicated in contributing to the acute disease by potential 
toxic effects of high cytokine levels, although the possibility remains 
that elevated proinflammatory cytokines are indicators rather than 
contributors to fatal disease (Ulett et al., 2000). Given the important 
role of proinflammatory cytokines in managing disease, it is difficult 
to address whether excessive levels of proinflammatory cytokines 
contribute to morbidity. Partial neutralization of IFN-γ by antibody 
depletion studies support the hypothesis that elevated proinflam-
matory cytokines do not themselves participate in morbidity in the 
mouse model, as depletion of IFN-γ results in a drastic increase in 
susceptibility to infection rather than protection from potential 
toxic effects (Santanirand et al., 1999). Caspase-1 knockout mice, 
which produced reduced levels of IFN-γ, are also more susceptible 
to melioidosis (Breitbach et al., 2009). Additionally, supplementa-
tion with IFN-γ in combination with low dose ceftazidime increased 
the survival of B. pseudomallei-infected BALB/c mice, suggesting 
that the proinflammatory response of BALB/c to B. pseudomallei is 
not itself contributing to morbidity (Propst et al., 2010). The criti-
cal role of IFN-γ in controlling melioidosis is shared by additional 
proinflammatory cytokines and host systems. Mutation or deple-
tion of IL-12p35, IL-12p40, and IL-18 increases the susceptibility 
of mice to challenge with B. pseudomallei, as does depletion of 
mature T cells (Haque et al., 2006). Defining the optimal IFN-γ 
concentration may help to address the role of IFN-γ in melioidosis, 
and address issues regarding potential therapeutic use of IFN-γ in 
treating melioidosis (Koh and Limmathurotsakul, 2010).
clInIcal relevance of Mouse Models
Mice represent an excellent surrogate for the study of clinical 
melioidosis given the similarity in the: (i) susceptibility to infec-
tion by multiple routes of infection, (ii) proinflammatory response 
to infection, and (iii) involvement of similar target organs. The 
lung, liver, and spleen are the primary sites of infection for both 
clinical and murine melioidosis as assessed by computerized tom-
ography (CT) and/or culture. While experimental murine melio-
idosis models allow for a quantitative analysis of bacterial burden 
in these organs by culture, little is known about clinical bacterial 
burdens given that diagnostic CT imaging of melioidosis provides 
qualitative pathological analyses. Future developments in clinical 
diagnostic imaging tools may facilitate quantitative comparisons 
of clinical bacterial burdens to the mouse model. Similarly, devel-
opments of diagnostic imaging in the mouse may reveal clinically 
relevant pathology, including the stereotypical “honeycomb” liver 
abscesses associated with melioidosis (Lim and Chong, 2010).
and Ketheesan, 2005), and given the lung involvement of transoral 
infections, the stomach would appear to be less susceptible to infec-
tion than the lung. A more recent study demonstrated a direct 
esophageal delivery of B. pseudomallei into BALB/c and C57BL/6 
mice results in oral LD
50
 values of greater than 7 × 108 CFU (West 
et al., 2010). These results suggest that mice are not susceptible to 
melioidosis by ingestion, which is consistent with evidence that 
human susceptibility to orally transmitted B. pseudomallei is not 
common (Inglis et al., 2000a).
chronIc Mouse Models
Characterizations of mouse susceptibility to B. pseudomallei 
infection identified a high susceptibility of BALB/c mice whereas 
C57BL/6 are thought to be relatively resistant (Leakey et al., 1998). 
This differential susceptibility to infection was used to classify 
BALB/c as an acute model whereas C57BL/6 challenge was thought 
to represent a model of chronic disease. Chronic clinical melioidosis 
is characterized by prolonged duration of the disease identified 
by evidence of persistence and relapse, and in endemic Thailand 
relapse typically occurs an average of 26 weeks following initial 
presentation (Limmathurotsakul et al., 2006). Unique incidents of 
relapse of 29 and 62 years post-infection have also been reported 
in humans (Chodimella et al., 1997; Ngauy et al., 2005).
The majority of murine melioidosis models published thus far 
have focused on characterization of acute disease occurring within 
the first several weeks of infection, with the exception of s.c. infec-
tions which may proceed beyond 6 weeks (Steward et al., 2005). TO 
mice are similarly resistant to melioidosis as C57BL/6, and an early 
study evaluating chronic persistence of B. pseudomallei in a low 
dose, i.p. TO mouse model found sterilizing clearance of bacteria 
from the spleen 4 weeks post-infection and non-quantifiable trace 
colonization of the liver (Santanirand et al., 1999). A more recent 
study found that low dose i.p. infection of BALB/c mice resulted 
in undetectable bacterial persistence beyond 5 days post-infection, 
using both PCR and culture techniques, with monitoring out to 
4 weeks (Srisurat et al., 2010). These findings suggest that mice 
surviving challenge with B. pseudomallei effectively clear bacteria 
by 4 weeks post-infection by the i.p. route with a low likelihood of 
chronic persistence.
Additional studies are required to evaluate the potential for a 
reproducibly chronic mouse model of melioidosis, with persist-
ence more closely mirroring the clinical reports. Resistant mouse 
strains such as TO and C57BL/6 mice may offer the best potential 
for developing a chronic disease state, and the prolonged course of 
the disease of the s.c. route of infection may lend itself to establish-
ing a chronic persistence.
host response to InfectIon
The host cytokine responses detected during murine melioido-
sis indicate that B. pseudomallei elicits a strong proinflammatory 
response, paralleling what is observed in clinical melioidosis. Initial 
investigations characterizing the host response in murine melio-
idosis sought to define potential differences in the host response 
to melioidosis in different mouse strains. It has long been known 
that C57BL/6 mice are less susceptible to melioidosis than other 
mouse strains such as BALB/c, and it was initially hypothesized 
that differential susceptibility may be due to a variation in the 
Frontiers in Microbiology | Cellular and Infection Microbiology  December 2010 | Volume 1 | Article 141 | 8
Warawa Burkholderia pseudomallei animal models
organisms in BALB/c mice (Wikraiphat et al., 2009), suggesting that 
hamsters are 103-fold more sensitive to systemic infections than the 
mouse. Thus, investigation of B. pseudomallei virulence determinant 
mutant attenuation in the hyper-sensitive hamster model results in 
convincing demonstration of the importance of certain genetic loci 
given the susceptibility of these animals to melioidosis.
The s.c. and aerosol routes of infection have also been used to 
model melioidosis in the hamster model, but given the extreme 
sensitivity of hamsters to infection, the small differences in LD
50
 
addItIonal anIMal Models
haMster
Hamster models of melioidosis are typically associated with a rap-
idly fatal acute disease. The intraperitoneal method of infection has 
been frequently used to identify critical B. pseudomallei virulence 
determinants in the Golden Syrian hamster model where wild type 
B. pseudomallei strains typically have 2 day LD
50
 values of fewer than 
10 organisms (Table 3). This is in contrast with the mouse i.p. model 
where the 1026b strain, studied in both models, has an LD
50
 of 104 
Table 3 | Other animal infection models.
Route of 
infection
Animal Sex Age or 
weight
Bacterial 
strain
LD50 or ID50 
(CFU)
Duration of 
observation
Reference(s)
i.p. Golden Syrian 
hamster
Female 6–8 weeks DD503 4, <10 2 days Moore et al. (1999), Warawa and Woods 
(2005)
i.p. Golden Syrian 
hamster
Female 6–8 weeks E300 <2 2 days Brett et al. (1997)
i.p. Golden Syrian 
hamster
Female 6–8 weeks 316c <10 2 days Brett et al. (1997)
i.p. Golden Syrian 
hamster
Female 6–8 weeks 1026b <10, <12, <2, 
<5
2 days Brett et al. (1997), DeShazer et al. (1997, 
1998), Jones et al. (1997), Moore et al. 
(1999), Reckseidler et al. (2001)
i.p. Golden Syrian 
hamster
Female 6–8 weeks 406e <10 2 days Moore et al. (2004)
i.p. Golden hamster Female 3–8 months 103-67 16 N.I. Dannenberg and Scott (1958)
Aerosol Golden hamster N.I. 3–8 months 103-67 16 N.I. Dannenberg and Scott (1958)
i.p. Golden hamster N.I. N.I. C-141 9.5 45 days Manzeniuk et al. (1999)
s.c. Golden hamster N.I. N.I. C-141 3.6 45 days Manzeniuk et al. (1999)
i.p. Hamster N.I. N.I. W294 6 20–30 days Miller et al. (1948)
s.c. Hamster N.I. N.I. W294 10 20–30 days Miller et al. (1948)
Aerosol Hamster N.I. N.I. W294 70 20–30 days Miller et al. (1948)
i.p. Landrace pig Mix 2 months 2796 >5.0 × 109 30 days Najdenski et al. (2004)
i.p. Ferret N.I. N.I. W294 <76 15 days Miller et al. (1948)
i.p. Hartley guinea pig Female 3–4 weeks 1026b 2 × 103 21 days DeShazer et al. (1998)
i.p. Guinea pig N.I. N.I. W294 440 N.I. Miller et al. (1948)
i.p. Guinea pig N.I. N.I. C-141 5.5 45 days Manzeniuk et al. (1999)
s.c. Guinea pig N.I. N.I. C-141 4.6 45 days Manzeniuk et al. (1999)
i.p. White rat N.I. N.I. C-141 4.4 × 104 45 days Manzeniuk et al. (1999)
s.c. White rat N.I. N.I. C-141 1.1 × 106 45 days Manzeniuk et al. (1999)
i.p. Sprague-Dawley 
infant diabetic rat
Male 50 g 1026b 1.9 × 104, 
2 × 104
7 days DeShazer et al. (1997, 1998), Jones et al. 
(1997)
i.p. Sprague-Dawley 
infant diabetic rat
Male 50 g 316c 9.53 × 103 avg N.I. Woods et al. (1993)
i.p. Sprague-Dawley rat Male 50 g 316c >1 × 108 N.I. Woods et al. (1993)
i.t. Sprague-Dawley rat Male 200–220 g 1026b 4 × 104 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g 319a <102 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g VN-Rat <102 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g 1106a 1.3 × 102 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g 1106b 2 × 102 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g 1710a 1.6 × 102 3 days van Schaik et al. (2008)
i.t. Sprague-Dawley rat Male 200–220 g 1710b 2 × 102 3 days van Schaik et al. (2008)
<TL>i.t. Sprague-Dawley rat Male 200–220 g DD503 4.6 × 104 3 days van Schaik et al. (2009)
i.p., Intraperitoneal; s.c., subcutaneous; i.t., intratracheal; N.I., not indicated.
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into current day melioidosis animal models, and there is now a 
renewed interest in developing non-human primate models given 
the potential translational relevance to clinical melioidosis. The 
Miller et al. study found that a rhesus macaque infected s.c. with 
1.5 × 106 CFU of B. pseudomallei developed transient subcutane-
ous abscesses which healed within 2 weeks, and 2 months post-
infection, no organisms were found in host tissues (Miller et al., 
1948). A more recent study found that Hamadryas baboons are 
susceptible to melioidosis by i.p. and s.c. routes of infection with 
a rapid disease involving lungs, liver, spleen, and lymph nodes 
(Manzeniuk et al., 1999). Consistent with the varying suscepti-
bility of mouse strains to melioidosis, a range of susceptibility is 
observed amongst non-human primate species, as is the case for 
the extreme susceptibility of gorillas to melioidosis (Yap et al., 
1995). Studies are ongoing to identify non-human primate models 
suitable for modeling clinical disease, with a focus on respiratory 
disease models.
The naturally occurring infection of livestock animals has 
been recently modeled in the laboratory for pigs. Pigs are con-
sidered to be moderately to highly resistant to infection relative 
to other livestock species (Choy et al., 2000). Consistent with 
these observations, experimental infection of Landrace pigs with 
a high-dose i.v. infection (5.0 × 109 CFU) failed to elicit a symp-
tomatic infection. Bacteria were cultured from the lung, liver, 
spleen, and mesenterial lymph nodes with immediate clearance 
initiated from day 1 with the exception of lung which peaked 
in colonization at day 3 (Najdenski et al., 2004). These findings 
suggest that pigs may be more susceptible to respiratory rather 
than systemic disease.
Invertebrate Models
Numerous pathogenic organisms are transmitted by insect vec-
tor, and the significant host range of B. pseudomallei suggests that 
insects may also be susceptible to melioidosis and/or vectors of 
disease. Xenopsylla cheopis fleas and Aëdes aegypti mosquitoes 
have been used to study the transmission of B. pseudomallei to 
guinea pigs (Blanc and Baltazard, 1949). Both fleas and mosqui-
toes were demonstrated to be able to acquire infection from a B. 
pseudomallei-infected guinea pig and in turn transmit disease to 
naïve guinea pigs. The role of fleas and mosquitoes as vectors for 
transmitting melioidosis has not been further investigated in the 
laboratory, however, an investigation of bacterial species naturally 
carried by syanthropic flies in Malaysia found that of the four fly 
species trapped, all four were carriers of B. pseudomallei, with 
Chrysomya megacephala representing the most frequent carrier 
(Sulaiman et al., 2000). Another investigation of B. pseudomallei 
transmission by ticks revealed that infected rabbits could transmit 
infection to the tick species Rhipicephalus bursa and Haemaphysalis 
punctata and that B. pseudomallei was successfully collected from 
the tick feces (Kharbov et al., 1981). Given the range of animal 
species susceptible to infection by B. pseudomallei, it is not unex-
pected that insects could be carriers of melioidosis. However, the 
role of insects as natural transmission vectors has not been well 
studied, likely due to the ease with which B. pseudomallei may be 
cultured directly from the environment. Studies of insect carriage 
of B. pseudomallei may provide insights into their possible role as 
vectors of disease.
identified for alternate routes of infection do not permit conclu-
sions about varied susceptibility of hamsters based on the route 
of infection. Aerosol delivery of strain 103-67 did not result in an 
altered LD
50
 relative to i.p. infection, however a similar study using 
strain W294 identified a 12-fold decrease in virulence by aerosol 
delivery (Table 3). Future studies may be required to define the 
susceptibility of hamsters to respiratory disease.
rat
Rat models of melioidosis have primarily focused on i.p. or i.t. 
infection methods, modeling septicemic and respiratory diseases, 
respectively. Initial studies describing the i.p. route of infection 
of Sprague-Dawley rats found that infant rats were resistant to 
B. pseudomallei challenge of more than 109 organisms, however 
streptozotocin-induced diabetes increased infant rat susceptibility 
by over 105-fold (Woods et al., 1993). Thus, the infant diabetic rat 
model offers the potential to investigate the clinically important role 
of diabetes in an animal model. Non-diabetic Sprague-Dawley rats 
are relatively resistant to i.p. infection but are acutely susceptible 
to respiratory infection by the intratracheal route with LD
50
 values 
ranging from <102 to 4.0 × 104 CFU (van Schaik et al., 2008). These 
findings suggest that the rat has a higher resistance to respiratory 
melioidosis than mice, whereby i.t. infections of rats require 30- 
to 40-fold more organisms to establish disease than i.n. delivery 
of the same B. pseudomallei 1026b and DD503 strains in BALB/c 
mice (Tables 2 and 3).
A chronic pulmonary melioidosis rat model has also been 
developed which involves suspension of B. pseudomallei in agar 
beads before surgical intratracheal instillation to the lung. This 
model permits long term colonization of the lung with peak lung 
colonization at approximately 1 week post-infection, and chronic 
infections extending beyond 2 weeks. This model was developed 
using B. pseudomallei strain 1026b, which has a similar LD
50
 value 
by agar bead delivery as by delivery in PBS suspension (van Schaik 
et al., 2008). Thus, agar bead delivery of B. pseudomallei does not 
affect the overall virulence of the bacteria, but allows for a control-
led establishment of a long term chronic infection using sub-lethal 
doses of B. pseudomallei.
Commercially available tools for studying the immunology of 
the rat are limited in comparison to the mouse model. Excellent 
developments have been made in the study of melioidosis in the rat 
including intratracheally introduced pulmonary disease, chronic 
disease establishment and diabetes modeling. Future efforts may 
similarly translate these methods to the mouse model to permit 
access to the analytical tools required to investigate the host immune 
response in detail.
other MaMMalIan Models
An important 1948 study by Miller et al. reported on the suscep-
tibility of a wide range of laboratory animals to infection with 
B. pseudomallei (Miller et al., 1948). The authors infected numer-
ous animal species by a variety of routes of infection, including 
i.v., i.p., s.c., and aerosol, and concluded that hamsters and ferrets 
represent the most susceptible melioidosis animal models, guinea 
pigs and rabbits were moderately susceptible, while mice, rats, 
and non-human primates were only slightly susceptible to infec-
tion. Approximately half of these species have been developed 
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